Skip to main content

Spravato® Treatment in Tulsa, OK

Spravato® Treatment is available at 9228 S Mingo Rd, Suite 101 in Tulsa, OK.

LifeStance Health Tulsa, OK

9228 S Mingo Rd, Suite 101
Tulsa, OK 74133

Get Directions

Billing Phone:425-654-7020
Fax:918-518-7258

Hours of Operation

Monday7:30 AM - 4:30 PM
Tuesday7:30 AM - 4:30 PM
Wednesday7:30 AM - 4:30 PM
Thursday7:30 AM - 4:30 PM
Friday7:30 AM - 4:30 PM
SaturdayClosed
SundayClosed

Spravato® Treatments At LifeStance

Spravato® (esketamine) is an FDA-approved nasal spray for adults with treatment-resistant depression (TRD) and depressive symptoms of major depressive disorder (MDD) with suicidal thoughts or actions. Spravato® treatments are administered under the supervision of a healthcare provider in a safe, comfortable, and supportive clinic environment.

  • check-circle-whiteFDA-approved nasal spray
  • check-circle-whiteFor depression that hasn't responded to antidepressants
  • check-circle-whiteAdministered in-office under provider supervision
  • check-circle-whiteCovered by most insurance
  • check-circle-whiteWorks differently than traditional antidepressants

Mental Health Providers that offer Spravato® Treatment in Tulsa, Oklahoma

No Providers Found

There were no providers found near Oklahoma. Try a nearby city, broaden your search, or check back soon as our network grows.

Our Oklahoma Locations

We currently offer Spravato® treatments in select Oklahoma offices. Check for a location near you.

Tulsa

9228 S Mingo Rd, Suite 101,
Tulsa, OK 74133

918-727-2157

Edmond

2908 Astoria Way, Suite 150,
Edmond, OK 73034

405-378-2727

Moore

1113 SW 30th Ct, Suite B,
Moore, OK 73160

405-378-2727

Oklahoma City

4013 NW Expressway, Suite 105,
Oklahoma City, OK 73116

405-906-2695

Spravato® Treatment in Tulsa, Oklahoma FAQ

Researchers believe Spravato® works to treat depression by targeting the NMDA receptor and glutamate neurotransmitter system in your brain. Scientific studies have illuminated the importance of NMDA/glutamate in modulating mood, behavior, memory, and learning.

Yes. Spravato® was approved by the FDA in 2019. It is under patent until 2024, after which there will likely be generic equivalents on the market.

No. Spravato® should be taken in conjunction with an oral antidepressant. Insurance companies require a patient to be prescribed an oral antidepressant prior to approving treatment coverage. Spravato® is intended to supplement but not replace your current anti-depression treatment.

Research studies show an efficacy of 33-60% depending on the duration of treatment.

Addiction to or physical dependence on Spravato® was not found in over 1700 patients included in clinical trials. It is unlikely that Spravato® taken at the doses and frequency used to treat mood symptoms will lead to any dependence or addiction.

Yes. The efficacy of Spravato® has been evaluated in short-term clinical trials and one longer-term maintenance-of-effect trial. In one of the short-term studies, Spravato® demonstrated a statistically significant effect on the severity of depression. In the maintenance trial, patients who continued treatment with Spravato® plus an oral antidepressant experienced a statistically significant longer time to relapse of depressive symptoms.

In a clinical trial for Spravato®, 65% of patients responded to treatment, achieving a 50% or greater reduction in depressive symptoms and 32% were in remission, these patients did not meet criteria for depression. In addition, patients who had responded to Spravato® were 71% less likely to relapse if they continued the medication and if they had been in remission, they were 51% less likely to relapse.

Find Mental Health Care Clinics & Services Near You